Clinical trials: Treatment Resistant Depressive Disorder
Bipolar Depression, Bipolar Disorder
Theta-Burst Stimulation for Bipolar Depression
The purpose of this trial is to determine if intermittent theta-burst stimulation (iTBS) can reduce the symptoms of depression in treatment-resistant bipolar disorder.
- Conditions
- Bipolar Depression, Bipolar Disorder, Treatment- Resistant Bipolar Disorder, Type 2 Bipolar Disorder
- Trial name
- TRIBE (NCT06370988)
- Testing
- iTBS Stimulation
- Where
- 2 sites in Canada
- Volunteers
- 124 people
- Sponsor
- Centre for Addiction and Mental Health
Treatment Resistant Depression
Accelerated Intermittent Theta Burst Stimulation for Depressed Patients During the Covid-19 Pandemic
Repetitive Transcranial Magnetic Stimulation (rTMS) using intermittent theta burst stimulation (iTBS) has been found to be a non inferior protocol to standard rTMS for the treatment of major depressive disorder.
- Trial name
- NCT04935489
- Testing
- Intermittent Theta Burst Stimulation (form of repetitive transcranial magnetic stimulation) given in an accelerated form
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Ontario Shores Centre for Mental Health Sciences
Treatment Resistant Bipolar Depression
Adjunctive Oral KET-AD Capsules in Treatment Resistant Bipolar Depression
This study is testing a new oral ketamine treatment called KET-AD in adults with treatment-resistant bipolar depression (TRBD). The study will look at how safe and tolerable the treatment is, and whether it may help improve…
- Trial name
- NCT07644767
- Testing
- KET-AD
- Volunteers
- 160 people
- Sponsor
- Neurocentrx Pharma Pty Ltd
Depressive Disorder
Intramuscular Ketamine Versus Aripiprazole and Escitalopram in the Treatment of Resistant Depression
The treatment of resistant depression should be optimized aiming at complete remission of symptoms, a complex condition due to several factors.
- Trial name
- KETProject (NCT04234776)
- Testing
- Ketamine, Cognition, Suicide risk
- Where
- Brazil
- Volunteers
- 88 people
- Sponsor
- University of Sao Paulo
Major Depressive Disorder
The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression
The purposes of this study are to determine: Whether olanzapine plus fluoxetine in combination will help patients with treatment-resistant major depression.
- Trial name
- NCT00035321
- Testing
- Olanzapine, Fluoxetine
- Where
- 33 sites in United States, Canada
- Volunteers
- 600 people
- Sponsor
- Eli Lilly and Company
Epilepsy, Depressions, Refractory
Low Frequency TMS for Depression in Epilepsy
The purpose of this study is to determine if low-frequency transcranial magnetic stimulation (TMS) is safe and feasible for treating depressive symptoms in patients with epilepsy.
- Trial name
- LFTMS (NCT03105700)
- Testing
- Transcranial Magnetic Stimulation
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Depression
A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive Disorder
The purpose of this study is to evaluate the effectiveness and safety of JNJ26489112 compared with an active control (Venlafaxine XR) and placebo in patients with Treatment-Resistant Major Depressive Disorder.
- Trial name
- NCT01114698
- Testing
- Venlafaxine XR, JNJ26489112
- Where
- 14 sites in United States
- Volunteers
- 12 people
- Sponsor
- Janssen Research & Development, LLC
Treatment Resistant Major Depressive Disorder
Repeated Intranasal Esketamine Plus Almond Therapy in Participants With Treatment Resistant Depressive Disorder - 3 Month Extension Study
The purpose of this study is to determine if any improvements in depressive symptoms are maintained in the medium and longer-term (up to 3 months)
- Trial name
- ZYL-730-02 (NCT05438758)
- Testing
- Almond Therapy, Intranasal ketamine (Esketamine), Treatment as Usual
- Sponsor
- Zylorion Health
Treatment Resistant Depression
Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)
This study is looking at the efficacy, durability, safety, and tolerability of multiple single doses of Ketamine vs. active placebo for treating patients with treatment resistant depression who are taking an antidepressant that…
- Trial name
- NCT01920555
- Testing
- Ketamine
- Where
- 6 sites in United States
- Volunteers
- 99 people
- Sponsor
- Massachusetts General Hospital
Persistent Depressive Disorder, Treatment-resistant Depression
A Comparison of Two Psychotherapy Programs in Persistently Depressed Treatment-Resistant Inpatients
The purpose of this study is to compare the Cognitive Behavioral Analysis System of Psychotherapy (CBASP) conducted over 16 weeks (acute and continuation treatment) with Behavioral Activation (BA; same dose and duration) in…
- Trial name
- ChangePDD (NCT04996433)
- Testing
- inpatient CBASP individual therapy, inpatient CBASP group therapy, inpatient CBASP nurse contact
- Where
- 8 sites in Germany
- Volunteers
- 396 people
- Sponsor
- University of Greifswald
Major Depressive Disorder, Treatment Resistant Depression
Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:
This is a feasibility study and the goal of this project is to evaluate whether peak ACC GABA and glutamate, quantified as a CSF-corrected absolute concentration percent change from baseline, is associated with clinical…
- Conditions
- Major Depressive Disorder, Treatment Resistant Depression, Bipolar Depression
- Trial name
- NCT03573349
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mayo Clinic
Major Depressive Disorder
Pilot Study Comparing 10hz vs Theta Burst Stimulation
This pilot study aims at exploring the efficacy of iTBS compared to 10Hz protocol and explore potential biomarkers of treatment response
- Trial name
- NCT02800226
- Testing
- 10Hz, iTBS
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University of British Columbia
Treatment Resistant Depression
Linear Asymmetric rTMS in Adolescent Treatment-Resistant Depression: Treatment Durations From Ten Days to One Day
This is a pilot interventional study to investigate the acceptability, tolerability, and side effect profile for varying numbers of treatment sessions/day of a new rTMS treatment in adolescents with treatment-resistant depression…
- Trial name
- NCT03986658
- Testing
- Linear Asymmetric rTMS System
- Where
- Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- NeuroQore Inc.
Treatment-Resistant Depression
PINS Stimulator System for Patients With Treatment Resistant Depression
Evaluate the effects and safety of Deep Brain Stimulation (DBS) to treat on patients with Treatment-Resistant Depression (TRD) and using functional magnetic resonance imaging (fMRI)to evaluate the influence of acupuncture on…
- Trial name
- NCT02253355
- Testing
- Deep Brain Stimulation
- Volunteers
- 20 people
- Sponsor
- Beijing Pins Medical Co., Ltd
Depressive Disorder, Treatment-Resistant
A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression
The purpose of this study is to evaluate the efficacy of each individual dose of esketamine nasal spray, 56 milligram (mg) and 84 mg, compared with placebo nasal spray in improving depressive symptoms in participants with…
- Trial name
- NCT04599855
- Testing
- Esketamine 56 mg, Esketamine 84 mg
- Where
- 54 sites in United States
- Volunteers
- 477 people
- Sponsor
- Janssen Research & Development, LLC
Major Depression
Selenium as Augmentation Treatment for Sertraline Resistant Major Depression
The main goals of antidepressant treatments are to achieve remission of depressive episodes and prevent recurrences. However, clinical trials designed to approve antidepressants targets a response rate of at least 50%, which is…
- Trial name
- NCT02890212
- Testing
- selenium supplementation
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- University of Sao Paulo General Hospital
Treatment-Resistant Depression
Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)
The main purpose of this study was to evaluate safety and efficacy of a single injection of MIJ821 in addition to standard of care (SoC) pharmacological anti-depressant treatment in participants with treatment-resistant…
- Trial name
- NCT05454410
- Testing
- MIJ821 Subcutaneous Injection 1 mg, MIJ821 Subcutaneous Injection 4 mg, MIJ821 Subcutaneous Injection 10 mg
- Where
- 16 sites in United States, Japan and 2 more
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Major Depressive Disorder
Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression
The purpose of the study is to determine the efficacy, safety and pharmacokinetics of inhaled Esketamine in participants with treatment-resistant depression (TRD) in the course of Major Depressive Disorder (MDD).
- Trial name
- NCT03965858
- Testing
- Esketamine DPI - low dose, Esketamine DPI - medium dose, Esketamine DPI - high dose
- Where
- 12 sites in Poland
- Volunteers
- 88 people
- Sponsor
- Celon Pharma SA
Major Depressive Disorder, Recurrent Depressive Disorder
Deep Brain Stimulation in Patients With Chronic Treatment Resistant Depression
Major depressive disorders are real public health issues in terms of diagnosis and treatment. Some forms of depression are chronic and resistant to treatment (TRD). In these forms suicide risk is important.
- Conditions
- Major Depressive Disorder, Recurrent Depressive Disorder, Bipolar Disorder
- Trial name
- STHYM (NCT01973478)
- Testing
- DBS
- Where
- 5 sites in France
- Volunteers
- 9 people
- Sponsor
- Rennes University Hospital
Treatment Resistant Depression
InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression
Depression is a common condition, with serious negative effects on the health and quality of life of those affected. While there are currently various medications which attempt to treat depression, they often take a long time to…
- Trial name
- TREASURE (NCT06781697)
- Testing
- Ketamine, Oculus VR headset
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- Sunnybrook Health Sciences Centre